Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation

Takae Okuno; Sayaka Arakawa; Tatsuya Yoshida; Yuichiro Ohe

doi:10.1016/j.lungcan.2020.03.016

Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation

Lung Cancer. 2020 May:143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.

Authors

Takae Okuno¹, Sayaka Arakawa¹, Tatsuya Yoshida², Yuichiro Ohe¹

Affiliations

¹ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: tatyoshi@ncc.go.jp.

PMID: 32209253
DOI: 10.1016/j.lungcan.2020.03.016

No abstract available

Keywords: EGFR uncommon mutation; Epidermal growth factor receptor (EGFR) mutation; Leptomeningeal metastasis; Non-small cell lung cancer; Osimertinib; S768I.

Publication types

Case Reports
Letter

MeSH terms

Acrylamides / therapeutic use*
Aged
Aniline Compounds / therapeutic use*
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Meningeal Carcinomatosis / drug therapy*
Meningeal Carcinomatosis / genetics
Meningeal Carcinomatosis / secondary
Mutation*
Prognosis

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
osimertinib
EGFR protein, human
ErbB Receptors